Sai Bio Pharma Products Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.96 M
- Company Age 17 Year, 28 Days
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 2.20 M
- Revenue Growth %
- Profit Growth 11.96%
- Ebitda -8.81%
- Net Worth -6.46%
- Total Assets -4.84%
About Sai Bio Pharma Products
Sai Bio Pharma Products Private Limited (SBPPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 January 2008 and has a history of 17 years. Its registered office is in Darjiling, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.96 M.
The company has closed loans amounting to ₹2.20 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Banya Basu and Goutam Goswami serve as directors at the Company.
Company Details
-
Location
Darjiling, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232WB2008PTC121638
-
Company No.
121638
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Jan 2008
-
Date of AGM
30 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Sai Bio Pharma Products?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Banya Basu
|
Director | 11-Jan-2008 | Current |
|
Goutam Goswami
|
Director | 29-Feb-2016 | Current |
Financial Performance of Sai Bio Pharma Products.
Sai Bio Pharma Products Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 11.96% increase in profit. The company's net worth dipped by a decrease of 6.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sai Bio Pharma Products?
In 2017, Sai Bio Pharma Products had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kbs Vacation & Hospitality LimitedGoutam Goswami is a mutual person
Charges (Loans)
₹0
₹2.20 M
Charges Breakdown by Lending Institutions
- Bank Of India : 0.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 May 2008 | Bank Of India | ₹2.20 M | Satisfied |
How Many Employees Work at Sai Bio Pharma Products?
Unlock and access historical data on people associated with Sai Bio Pharma Products, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sai Bio Pharma Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sai Bio Pharma Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
